Co-Diagnostics Inc. shares climbed 58.4% in morning trading after the Salt Lake City molecular diagnostics company announced it had completed its assay development strategy for the Bundibugyo virus, the Ebola-causing strain currently linked to outbreaks in the Democratic Republic of the Congo and Uganda.
In a company press release, CEO Dwight Egan said: "We are pleased to report that we have completed the assay development strategy for BDBV, and should a situation arise requiring the assay, we expect we would be well positioned to execute the strategy and rapidly make the test available." The firm indicated it intends to use its Co-Dx PCR point-of-care platform for the Bundibugyo assay.
The announcement came as global health authorities intensified their response to the outbreak. On May 16, 2026, the WHO Director-General determined that the Ebola disease caused by Bundibugyo virus in the DRC and Uganda constitutes a public health emergency of international concern (PHEIC). The CDC also urgently coordinated with interagency partners on the outbreak and activated its Emergency Response Center.
Health officials have emphasized the limits of current medical countermeasures in this outbreak. The Bundibugyo virus is a rare Ebola-causing virus for which there are currently no licensed vaccines or therapeutics. That absence has heightened attention on diagnostic capabilities and any company that can present a credible testing response.
The U.S. Centers for Disease Control and Prevention has issued guidance calling for enhanced screening and monitoring of travelers from Ebola-affected regions. Those measures underscore the role rapid PCR testing and real-time outbreak visibility can play in public health responses - capabilities Co-Diagnostics says its Co-Dx PCR platform aims to support.
Financial results published for the first quarter of 2026 added context to the market reaction. Q1 revenue rose approximately 190% to $145,950, while the adjusted loss per share narrowed to $4.06 from $7.20 a year earlier. Revenue for the quarter exceeded the estimated $127,050, a modestly constructive backdrop for investor sentiment.
Market structure characteristics of Co-Diagnostics helped magnify the intraday move. Short interest in CODX currently stands at 16,800 shares - down 76.7% from the prior reporting period - representing only 0.9% of the float. Short interest has decreased 89.7% over the past twelve months, indicating limited short-covering pressure to amplify the rally.
Broader U.S. equity markets offered no tailwind on the session, with the S&P 500, Dow Jones, and NASDAQ all trading in negative territory during today’s session. Nevertheless, a convergence of a real-time global health emergency, a direct corporate response announcement, and a low-float micro-cap structure created the conditions for the outsized move in CODX.
It is important to note the Bundibugyo assay remains under regulatory review and is not yet available for sale. That regulatory status is a key caveat that could temper longer-term enthusiasm even as investors priced in the potential commercial and public health significance of the development.
What this means
- Co-Diagnostics announced completion of its assay development strategy for the Bundibugyo virus and plans to use its Co-Dx PCR point-of-care platform for the assay.
- The WHO designated the outbreak a PHEIC on May 16, 2026, and the CDC activated its Emergency Response Center and coordinated with interagency partners.
- Q1 2026 revenue increased roughly 190% to $145,950, and adjusted loss per share narrowed to $4.06 from $7.20 year-over-year.